Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
-
- José G. Montoya
- Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Amy E. Adams
- Palo Alto Foundation Medical Group, Palo Alto, California, USA
-
- Valérie Bonetti
- Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Sien Deng
- Center for Health Systems Research, Sutter Health, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Nan A. Link
- Palo Alto Foundation Medical Group, Palo Alto, California, USA
-
- Suzanne Pertsch
- Palo Alto Foundation Medical Group, Palo Alto, California, USA
-
- Kjerstie Olson
- Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Martina Li
- Center for Health Systems Research, Sutter Health, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Ellis C. Dillon
- Center for Health Systems Research, Sutter Health, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Dominick L. Frosch
- Center for Health Systems Research, Sutter Health, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA
-
- Daniel R. Perez
- editor
抄録
<jats:p>SARS-CoV-2 vaccines using the mRNA platform have become one of the most powerful tools to overcome the COVID-19 pandemic. mRNA vaccines enable human cells to produce and present the virus spike protein to their immune system, leading to protection from severe illness. Two mRNA vaccines have been widely implemented, mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech).</jats:p>
収録刊行物
-
- Microbiology Spectrum
-
Microbiology Spectrum 9 (3), 2021-12-22
American Society for Microbiology